comparemela.com

Latest Breaking News On - Ambuas stock exchange - Page 1 : comparemela.com

INTERIM REPORT FOR Q2 2022/23 AND THE HALF-YEAR

Ambu posts 4% organic revenue growth for the second quarter of 2022/23, in line with expectations. The quarter was driven by continued strong growth in urology and ENT, offset by pulmonology and. | May 3, 2023

Ambu A/S : obtains European regulatory clearance of its complete fifth-generation bronchoscope portfolio

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.